VR
Virax Biolabs Group Limited
VRAX · NASDAQ
$2.54 +1.60% (+$0.04)
1M -26.38%
Market Cap $50.4M
P/E Ratio -
Div. Yield -
ROE 73.80%
Piotroski F-Score Weak
2/9Valuation
9 /100
Expensive P/B 6.65x
P/S 4,057.50x
P/FFO N/A
Growth
62 /100
Stable Book val. growth 6.01%
Rev. growth 13.21%
FCF growth N/A
Profitability
20 /100
Weak Net margin 40,439.10%
Op. margin 51,515.20%
FCF margin 39,263.60%
Quality
0 /100
Poor ROE 73.80%
ROA 60.35%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 9.97x
Debt/Equity 0.05x
Net debt/EBITDA N/A
Stability
12 /100
Unstable Rev. volatility 1,001.69%
EPS volatility 338.60%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre VRAX
Online
Despre companie
Virax Biolabs Group Limited (VRAX) is a biotechnology company focusing on the research and development of drugs and therapeutic procedures in the field of infectious diseases and immunology.
Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.
Sector
Healthcare
Industry
Biotechnology
CEO
James Foster
Employees
26
Headquarters
Lanarkshire
Evenimente viitoare
02 DEC.
Earnings
Upcoming earnings report